1. Clinical Overview
Naloxone is a potent, competitive opioid receptor antagonist. In the 20mcg strength, it is primarily used as an adjunct in spinal or epidural anesthesia to mitigate opioid-induced side effects like pruritus and nausea, without reversing analgesia. It is a pure antagonist with no agonist activity, high affinity for mu-opioid receptors, and rapid onset of action.
| Onset | Duration | Bioavailability |
|---|---|---|
| Intravenous: 1-2 minutes; Intramuscular/Subcutaneous: 2-5 minutes; Epidural/Intrathecal: Variable, within minutes. | Short, typically 30-90 minutes, depending on route and dose. Duration may be shorter than that of the opioid being antagonized, necessitating monitoring for re-narcotization. | Intranasal: ~25-50%; Intramuscular/Subcutaneous: ~40-100% (variable); Oral: <2% due to extensive first-pass metabolism. |
2. Mechanism of Action
Naloxone competitively binds to opioid receptors (mu, kappa, delta) with high affinity, displacing opioid agonists and reversing or blocking their effects. At the 20mcg dose used in anesthesia, it preferentially antagonizes undesirable side effects (pruritus, nausea) mediated via mu-opioid receptors in the chemoreceptor trigger zone and spinal cord, while preserving supraspinal analgesia.
3. Indications & Uses
- Reversal of opioid-induced respiratory depression in a controlled hospital setting (though 20mcg is a sub-therapeutic dose for full reversal; used as an adjunct).
- Prophylaxis or treatment of pruritus induced by neuraxial (epidural/intrathecal) opioids.
- Prophylaxis or treatment of nausea and vomiting induced by neuraxial opioids.
4. Dosage & Administration
Adult Dosage: For opioid-induced pruritus/nausea in neuraxial anesthesia: 20-40 mcg (0.02-0.04 mg) IV bolus, repeated as needed. Often administered as a continuous infusion of 1-5 mcg/kg/hr. Maximum single dose for this indication is typically 100 mcg.
Administration: For 20mcg dose: Usually drawn from a 400mcg/mL or 1mg/mL ampoule and diluted. Administer IV slowly over 30-60 seconds. For epidural use, must be preservative-free. Continuous ECG, BP, and respiratory monitoring required. Have resuscitation equipment available.
5. Side Effects
Common side effects may include:
- Nausea
- Vomiting
- Sweating
- Tachycardia
- Hypertension
- Tremors
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Opioid Agonists (Morphine, Fentanyl, Pethidine) | Naloxone reverses analgesic and adverse effects. May precipitate withdrawal in dependent patients. | Major |
| Opioid Partial Agonists (Buprenorphine) | May be difficult to fully reverse effects due to high receptor affinity of buprenorphine. Larger/ repeated doses may be needed. | Major |
| Clonidine | Naloxone may reverse the hypotensive effects of clonidine. | Moderate |
| Cardiotoxic Drugs (e.g., Halothane) | Increased risk of ventricular arrhythmias. | Moderate |
7. Patient Counselling
- Do inform your anesthesiologist/surgeon if you have a history of opioid use or dependency.
- Do report any sudden pain, agitation, nausea, or sweating after receiving the medication.
- Don't assume you are free from opioid effects after naloxone; sedation may return ('renarcotization').
- Don't drive or operate heavy machinery for at least 24 hours after the procedure.
8. Toxicology & Storage
Overdose: Naloxone itself has no major toxic effects in the absence of opioids. In patients on opioids, it causes acute withdrawal. In non-opioid users, very high doses may cause nausea, vomiting, tachycardia, and hypertension.
Storage: Store at controlled room temperature (15-25°C). Protect from light. Do not freeze. Keep in the original packaging. For ampoules, use immediately after opening. Do not use if solution is discolored or contains particulate matter.